HDAC9 and cancer: Mechanistically, the tumor microenvironment and specific anti-tumor immune responses might be affected by HDAC inhibitors at several distinct levels, including the stimulation of cancer antigens’ expression or MHC class I/II expression, the modulation of immunosuppressive signaling pathways, the reduction in immunosuppressive cell populations, or the enrichment of chemokine expression [77,78].